Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows
Company

Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump
Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

CompanyDrug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

CompanyDeals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

CompanyDrug

Marubeni Launches Xenleta in China After Complex Licensing Journey

CompanyDrug

CMS-D017 Gets NMPA Approval for Complement-Mediated Kidney Disease Study

CompanyDeals

Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China

CompanyDrug

United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial

CompanyDrug

Wuhan YZY Biopharma Gets FDA Nod for M701 Phase Ib/II MPE Study

Amgen Q4 Revenue Grows 9% to $9.9B on Strong Product Sales
Company

Amgen Q4 Revenue Grows 9% to $9.9B on Strong Product Sales

CompanyDeals

Grand Pharmaceutical to Acquire API Firms for RMB 316 Million

Novo Nordisk Sales Reach DKK 309 Billion on GLP‑1 and Obesity Surge
Company

Novo Nordisk Sales Reach DKK 309 Billion on GLP‑1 and Obesity Surge